Medicare Enrolled
Dr. Haresh Jhangiani, M.D.
Optician · Fountain Valley, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jhangiani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jhangiani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jhangiani
Dr. Haresh Jhangiani is an optician specialist in Fountain Valley, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jhangiani performed 2,975 Medicare services across 262 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jhangiani received a total of $85,378 from 110 pharmaceutical and/or device companies across 2014 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jhangiani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 28% volume in CA
$85,378 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,975
Medicare services
Top 28% in CA for optician
262
Unique beneficiaries
$39
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~149 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,860 | $18 | $40 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
553 | $97 | $250 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
156 | $114 | $290 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
148 | $6 | $25 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
109 | $26 | $75 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
84 | $12 | $75 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
47 | $54 | $150 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $140 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.5% high complexity
70.3% medium
19.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$85,378
Total received (2018-2024)
Avg $12,197/year across 7 years
Top 4% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
110
Companies
2,014
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$40,552 (47.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$36,966 (43.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$7,860 (9.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$12,456
2023
$6,875
2022
$8,101
2021
$14,611
2020
$9,879
2019
$12,466
2018
$20,991
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$5,555
Janssen Biotech, Inc.
$765
Merck Sharp & Dohme LLC
$516
AstraZeneca Pharmaceuticals LP
$509
Novartis Pharmaceuticals Corporation
$482
Alexion Pharmaceuticals, Inc.
$442
Takeda Pharmaceuticals U.S.A., Inc.
$351
Eisai Inc.
$309
Celgene Corporation
$307
PUMA BIOTECHNOLOGY, INC.
$263
Exelixis Inc.
$229
GlaxoSmithKline, LLC.
$217
ABBVIE INC.
$212
PFIZER INC.
$204
BeiGene USA, Inc.
$190
Daiichi Sankyo Inc.
$181
Incyte Corporation
$177
E.R. Squibb & Sons, L.L.C.
$152
GENZYME CORPORATION
$141
Astellas Pharma US Inc
$132
ARRAY BIOPHARMA INC
$99
Bayer Healthcare Pharmaceuticals Inc.
$86
Karyopharm Therapeutics Inc.
$79
PharmaEssentia USA Corporation
$60
JAZZ PHARMACEUTICALS INC.
$58
Boehringer Ingelheim Pharmaceuticals, Inc.
$58
Tempus AI, Inc
$55
Mirati Therapeutics, Inc.
$48
Rigel Pharmaceuticals, Inc.
$47
RECORDATI_RARE_DISEASES_INC.
$45
TAIHO ONCOLOGY, INC.
$43
Coherus Biosciences Inc.
$41
Regeneron Healthcare Solutions, Inc.
$35
Kite Pharma, Inc.
$34
TerSera Therapeutics LLC
$34
Genentech USA, Inc.
$34
Stemline Therapeutics Inc.
$34
Adaptive Biotechnologies Corporation
$33
Verity Pharmaceuticals Inc.
$29
ImmunoGen, Inc.
$25
Blueprint Medicines Corporation
$25
Legend Biotech USA Inc.
$24
Agios Pharmaceuticals, Inc.
$22
Lilly USA, LLC
$22
Aveo Pharmaceuticals, Inc.
$21
SOBI, INC
$19
Emmaus Medical, Inc.
$12
Top 3 companies account for 54.9% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$10,943
Incyte Corporation
$7,151
Gilead Sciences, Inc.
$6,650
Coherus Biosciences Inc.
$6,011
AstraZeneca Pharmaceuticals LP
$4,304
Takeda Pharmaceuticals U.S.A., Inc.
$4,278
PFIZER INC.
$3,868
Janssen Biotech, Inc.
$3,403
AMAG Pharmaceuticals, Inc.
$3,077
Karyopharm Therapeutics Inc.
$2,788
AbbVie, Inc.
$2,432
Heron Therapeutics, Inc.
$2,417
Novartis Pharmaceuticals Corporation
$2,040
Seagen Inc.
$2,038
E.R. Squibb & Sons, L.L.C.
$1,668
Amgen Inc.
$1,544
Athenex Pharmaceutical Division, LLC
$1,250
Merck Sharp & Dohme LLC
$1,119
GlaxoSmithKline, LLC.
$1,093
Eisai Inc.
$1,005
Astellas Pharma US Inc
$938
Merck Sharp & Dohme Corporation
$883
Pharmacyclics LLC, An AbbVie Company
$749
Alexion Pharmaceuticals, Inc.
$719
Genentech USA, Inc.
$706
Exelixis Inc.
$685
GENZYME CORPORATION
$639
Daiichi Sankyo Inc.
$582
Pharmacyclics LLC, an AbbVie Company
$521
Bayer HealthCare Pharmaceuticals Inc.
$500
BeiGene USA, Inc.
$498
PUMA BIOTECHNOLOGY, INC.
$479
ARRAY BIOPHARMA INC
$433
Regeneron Healthcare Solutions, Inc.
$374
Boehringer Ingelheim Pharmaceuticals, Inc.
$371
Lilly USA, LLC
$350
ABBVIE INC.
$328
Bayer Healthcare Pharmaceuticals Inc.
$306
Blueprint Medicines Corporation
$305
NOVARTIS PHARMACEUTICALS CORPORATION
$303
Rigel Pharmaceuticals, Inc.
$290
Kite Pharma, Inc.
$281
EISAI INC.
$233
Jazz Pharmaceuticals Inc.
$223
Puma Biotechnology, Inc.
$202
Epizyme, Inc.,
$198
AVEO Pharmaceuticals, Inc.
$190
EMD Serono, Inc.
$189
Stemline Therapeutics Inc.
$174
Deciphera Pharmaceuticals Inc.
$163
Ipsen Biopharmaceuticals, Inc
$146
AbbVie Inc.
$142
Taiho Oncology, Inc.
$140
Octapharma USA, Inc.
$130
Myovant Sciences Inc.
$129
Foundation Medicine, Inc.
$113
Array BioPharma Inc.
$109
MorphoSys, US Inc.
$107
Adaptive Biotechnologies Corporation
$107
Agios Pharmaceuticals, Inc.
$103
TAIHO ONCOLOGY, INC.
$103
SANOFI-AVENTIS U.S. LLC
$100
Sobi, Inc
$96
Ethicon Inc.
$96
PharmaEssentia USA Corporation
$95
Aveo Pharmaceuticals, Inc.
$91
TerSera Therapeutics LLC
$91
Seattle Genetics, Inc.
$86
Clovis Oncology, Inc.
$83
TESARO, Inc.
$81
JAZZ PHARMACEUTICALS INC.
$79
Immunocore Limited
$77
Mirati Therapeutics, Inc.
$65
Pharmacosmos Therapeutics Inc.
$61
MEDIVATION FIELD SOLUTIONS LLC
$57
Tempus AI, Inc
$55
Kyowa Kirin, Inc.
$54
Verity Pharmaceuticals Inc.
$52
SOBI, INC
$52
Dendreon Pharmaceuticals LLC
$49
Sumitomo Pharma America, Inc.
$48
Dova Pharmaceuticals
$47
RECORDATI_RARE_DISEASES_INC.
$45
Acrotech Biopharma LLC
$42
Organon LLC
$39
Helsinn Therapeutics (U.S.), Inc.
$38
Teva Pharmaceuticals USA, Inc.
$37
Novocure Inc.
$33
EUSA Pharma (US) LLC
$28
Amneal Pharmaceuticals LLC
$27
Spectrum Pharmaceuticals Inc.
$26
ImmunoGen, Inc.
$25
Sirtex Medical Inc
$25
Legend Biotech USA Inc.
$24
Catalyst Pharmaceuticals, Inc.
$24
G1 Therapeutics, Inc.
$23
Lexicon Pharmaceuticals, Inc.
$21
Otsuka America Pharmaceutical, Inc.
$21
Secura Bio, Inc.
$19
TG Therapeutics, Inc.
$18
Alnylam Pharmaceuticals Inc.
$17
Myriad Genetic Laboratories, Inc.
$15
West Therapeutics Development, LLC
$14
SERVIER PHARMACEUTICALS LLC
$13
GE HEALTHCARE
$13
Partner Therapeutics, Inc.
$13
Emmaus Medical, Inc.
$12
Global Blood Therapeutics, Inc.
$12
Mylan Pharmaceuticals Inc.
$11
Janssen Pharmaceuticals, Inc
$7
Top 3 companies account for 29.0% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Biktarvy · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMEND · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EVENITY · EXKIVITY · Endari · Enhertu · Erleada · FARESTON · FARYDAK · FASLODEX · FERAHEME · FIRDAPSE · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · Fulphila · GAMIFANT · GAVRETO · GILOTRIF · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LEUKINE · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lazanda · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · Monarch Platform · Monoferric · NERLYNX · NEUPOGEN · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORENCIA · ORGOVYX · OXBRYTA · Oncology · Onivyde · Oral Paclitaxel · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Polivy · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYLVANT · Stivarga · Sylvant · TAGRISSO · TALVEY · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trelstar · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · XYNTHA · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · Zydelig · clonoSEQ · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (48%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 4% for optician in CA.
Geographic Context
Opticians within 10 mi
1,016
Per 100K population
32.1
County median income
$113,702
Nearest hospital
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jhangiani is a clinical cardiology specialist, with above-average Medicare volume (top 28% in CA), with consulting-driven industry engagement in the top 4% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jhangiani experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Jhangiani performed 1,860 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jhangiani receive payments from pharmaceutical companies?
Yes. Dr. Jhangiani received a total of $85,378 from 110 companies across 2,014 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jhangiani's costs compare to other opticians in Fountain Valley?
Dr. Jhangiani's average Medicare payment per service is $39. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jhangiani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Fountain Valley
Browse opticians in Fountain Valley ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology